Small cell lung cancer extensive stage
Not recruitingStudy on the Effectiveness and Safety of Pembrolizumab, Quavonlimab, and Lenvatinib for Patients with Advanced Small Cell Lung Cancer Needing Second-Line Treatment
Study on the Effectiveness and Safety of Pembrolizumab, Quavonlimab, and Lenvatinib for Patients with Advanced Small Cell Lung Cancer Needing Second-Line Treatment
- Disease:Small cell lung cancer extensive stage
- Substances:FavezelimabLenvatinib+4
Austria- Participants:18–64 years · 65+ years
- Substances:Favezelimab
- Sponsor:Merck Sharp & Dohme LLC














